Scholarlink

<p>Messenger mRNA vaccine technology proved highly effective during the COVID-19 pandemic and now demonstrating equally strong potential for preventing and treating non-communicable diseases including cancer, autoimmune disorders and hypertension. Unlike traditional vaccines for infectious diseases that target pathogens, researchers design mRNA vaccine to encode antigens involved in chronic disease development and progression. This approach enables preventive and therapeutic applications such as activating immune cells to eliminate cancer cells or regulate harmful immune responses. Recent advances in cancer immunotherapy highlight the successful targeting of tumor-specific neoantigens. However, scientists must address challenges or limitations such as identifying safe antigens, ensuring long term safety, increase delivery efficiency, improving bioavailability and designing robust clinical trials. Despites this limitation, mRNA vaccines show a transformative strategy for NCD management, with advanced approaches utilizing personalized neoantigen encoding, telerogenic mRNA construct, and lipid nanoparticle mediated targeted delivery are being explored to enhance immunogenic precision, therapeutic efficacy, and clinical translation especially in cancer and autoimmune disorders. Integrating this innovation into national health policies, regulatory frameworks, and public funding strategies will promote equitable access, affordability, and sustainable implementation within global healthcare systems.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

mRNA Vaccines as a Transformative Tool in Non-Communicable Diseases Prevention and Treatment

  • 期刊论文

  • 发表日期：

    2026年6月29日

查看全文
  • Anshika Jat,
  • Rudraksh Mukherjee,
  • Payal Sharma,
  • Shikha Tiwari

摘要

Messenger mRNA vaccine technology proved highly effective during the COVID-19 pandemic and now demonstrating equally strong potential for preventing and treating non-communicable diseases including cancer, autoimmune disorders and hypertension. Unlike traditional vaccines for infectious diseases that target pathogens, researchers design mRNA vaccine to encode antigens involved in chronic disease development and progression. This approach enables preventive and therapeutic applications such as activating immune cells to eliminate cancer cells or regulate harmful immune responses. Recent advances in cancer immunotherapy highlight the successful targeting of tumor-specific neoantigens. However, scientists must address challenges or limitations such as identifying safe antigens, ensuring long term safety, increase delivery efficiency, improving bioavailability and designing robust clinical trials. Despites this limitation, mRNA vaccines show a transformative strategy for NCD management, with advanced approaches utilizing personalized neoantigen encoding, telerogenic mRNA construct, and lipid nanoparticle mediated targeted delivery are being explored to enhance immunogenic precision, therapeutic efficacy, and clinical translation especially in cancer and autoimmune disorders. Integrating this innovation into national health policies, regulatory frameworks, and public funding strategies will promote equitable access, affordability, and sustainable implementation within global healthcare systems.